Lofti Benboubker
Overview
Explore the profile of Lofti Benboubker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
973
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bobin A, Manier S, De Keizer J, Srimani J, Hulin C, Karlin L, et al.
Haematologica
. 2024 Nov;
110(3):758-763.
PMID: 39540213
No abstract available.
2.
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, et al.
Blood
. 2022 May;
139(18):2747-2757.
PMID: 35511184
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a...
3.
Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, et al.
Immunotherapy
. 2020 Nov;
13(2):143-154.
PMID: 33228440
To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. We conducted an unanchored matching-adjusted indirect comparison of progression-free and...
4.
Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, et al.
Blood
. 2018 Oct;
132(24):2555-2563.
PMID: 30282798
It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage....
5.
Augeul-Meunier K, Chretien M, Stoppa A, Karlin L, Benboubker L, Torregrosa Diaz J, et al.
Bone Marrow Transplant
. 2018 Mar;
53(6):749-755.
PMID: 29523884
Renal impairment is a common complication of multiple myeloma (MM), accounting for 20-30% of MM patients at diagnosis and 40-50% of patients during the course of their disease. This feature...
6.
Kumar S, Kaufman J, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al.
Blood
. 2017 Oct;
130(22):2401-2409.
PMID: 29018077
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to...
7.
Owens C, Laurence V, Benboubker L, Defachelles A, Cupissol D, Rubie H, et al.
Cancer Chemother Pharmacol
. 2012 Nov;
71(2):399-404.
PMID: 23161409
Background: Phase II trials demonstrate the activity of cisplatin in patients with refractory Ewing sarcoma family tumours (ESFT) and also the feasibility of giving cisplatin with oral VP16 in a...
8.
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al.
N Engl J Med
. 2012 May;
366(19):1782-91.
PMID: 22571202
Background: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse....
9.
Harousseau J, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa A, et al.
Haematologica
. 2006 Oct;
91(11):1498-505.
PMID: 17043025
Background And Objectives: Induction regimens prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients usually result in complete remission (CR) rates of <10%. The use of...
10.
Attal M, Harousseau J, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al.
Blood
. 2006 Jul;
108(10):3289-94.
PMID: 16873668
Newer chemotherapeutic protocols as well as high-dose chemotherapy have increased the response rate in myeloma. However, these treatments are not curative. Effective maintenance strategies are now required to prolong the...